We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+21.91%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$154M
AUM Growth
-$35M
Cap. Flow
-$41.2M
Cap. Flow %
-26.76%
Top 10 Hldgs %
66.56%
Holding
37
New
5
Increased
7
Reduced
9
Closed
11

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$17M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$8.18M
3
RZLT icon
Rezolute
RZLT
+$8.17M
4
LEGN icon
Legend Biotech
LEGN
+$6.86M
5
AKRO
Akero Therapeutics
AKRO
+$4.72M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$10.1M
2
MRUS
Merus
MRUS
+$9.98M
3
KALV
KalVista Pharmaceuticals
KALV
+$8.45M
4
AKBA icon
Akebia Therapeutics
AKBA
+$8.21M
5
ASND icon
Ascendis Pharma A/S
ASND
+$7.79M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBOT
26
BridgeBio Oncology
BBOT
$715M
$312K 0.2%
29,381
-344,452
-92% -$3.72M
ASND icon
27
Ascendis Pharma A/S
ASND
$16.8B
– –
-50,000
Closed -$7.79M
AUTL
28
Autolus Therapeutics
AUTL
$397M
– –
-2,728,910
Closed -$4.23M
BEAM icon
29
Beam Therapeutics
BEAM
$2.6B
– –
-175,562
Closed -$3.43M
DNTH icon
30
Dianthus Therapeutics
DNTH
$5.74B
– –
-275,000
Closed -$4.99M
DVAX
31
DELISTED
Dynavax Technologies
DVAX
– –
-595,879
Closed -$7.73M
MREO
32
Mereo BioPharma
MREO
$45.5M
– –
-1,275,000
Closed -$2.87M
MRUS
33
DELISTED
Merus
MRUS
– –
-237,156
Closed -$9.98M
PCVX icon
34
Vaxcyte
PCVX
$8.05B
– –
-115,517
Closed -$4.36M
SMMT icon
35
PUT
Summit Therapeutics
SMMT
$10.8B
– –
-250,000
Closed -$4.82M
VRDN icon
36
Viridian Therapeutics
VRDN
$2.2B
– –
-750,000
Closed -$10.1M
VYGR icon
37
Voyager Therapeutics
VYGR
$186M
– –
-626,275
Closed -$2.12M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $436M AUM
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Great Point Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Great Point Partners held 37 positions worth $154M, down 19% from $189M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Great Point Partners withdrew a net $41.2M in Q2 2025, closing 11 positions and reducing 9 holdings. Its most notable exit was Viridian Therapeutics, an estimated $10.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Jade Biosciences worth $4.98M.

  • Great Point Partners's largest Q2 2025 buy was Jade Biosciences: 498,054 shares worth $4.98M.
  • Great Point Partners added most to Ionis Pharmaceuticals in Q2 2025, an estimated $8.18M increase.
  • Great Point Partners's biggest Q2 2025 reduction was KalVista Pharmaceuticals, cutting an estimated $8.45M.
  • Great Point Partners fully exited Viridian Therapeutics in Q2 2025, selling an estimated $10.1M.
  • Great Point Partners's ten largest holdings make up 67% of its $154M portfolio in Q2 2025.
  • Great Point Partners opened 5 new positions and closed 11 in Q2 2025.
  • Great Point Partners's portfolio value fell 19% quarter-over-quarter to $154M.

Based on Great Point Partners's 13F filing for Q2 2025, filed 14 Aug 2025.